Source comparison
Tesamorelin vs Sermorelin
Sermorelin is an older GHRH analogue comprising the first 29 amino acids of endogenous GHRH — sufficient for GHRH receptor binding and activation. It was the first GHRH analogue to receive FDA approval (for paediatric GH deficiency, 1997), though it was subseq
This comparison does not assign a generated winner or score.
- Sermorelin is an older GHRH analogue comprising the first 29 amino acids of endogenous GHRH — sufficient for GHRH receptor binding and activation. It was the first GHRH analogue to receive FDA approval (for paediatric GH deficiency, 1997), though it was subsequently withdrawn from the U.S. market for commercial rather than safety reasons. Structurally, sermorelin differs from tesamorelin in that it lacks the full 44-amino acid sequence and the stabilising fatty acid modification. Tesamorelin’s greater receptor binding affinity and longer functional duration in plasma give it a more potent and sustained effect compared with sermorelin at equivalent doses. The clinical evidence base for tesamorelin in adult metabolic indications substantially exceeds that for sermorelin, which has been studied primarily in smaller Phase 2 trials in older adult and anti-ageing medicine contexts.